A combination of NHS-IL12 and anti PD-L1 antibody avelumab demonstrated a synergistic anti-tumor effect in MC38 and MB49 tumor-bearing C57BL/6 mice and seems to be promising for tumor cotreatment [90]. This evidence concerns the gene CD274 and neoplasm.